cisplatin + flavopiridol

Cisplatin + flavopiridol is an investigational combination therapy consisting of cisplatin, a platinum-based DNA crosslinking agent that induces apoptosis by causing DNA damage, and flavopiridol (also known as alvocidib), a small molecule cyclin-dependent kinase (CDK) inhibitor. Flavopiridol inhibits CDKs involved in cell cycle progression and transcription, leading to cell cycle arrest and apoptosis. The combination has been studied primarily in advanced solid tumors and ovarian/primary peritoneal cancers to assess safety, pharmacokinetics, toxicity profiles, and preliminary efficacy. Clinical trials have shown that the regimen can be safely administered with manageable toxicities at defined doses; it has demonstrated clinical activity in both platinum-sensitive and resistant cancers[1][2][5].